Pirkko-Liisa Kellokumpu-Lehtinen

Professor of Radiotherapy and Oncology, emerita

Tampere University

Finland

Research Interests

Explore related searches

Professors in Finland Professors in Medical Imaging Medical Imaging professors in Finland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Pirkko-Liisa Kellokumpu-Lehtinen is an emerita faculty member at Tampere University in Finland. Her research focuses on radiotherapy and oncology, with recent publications addressing biomarkers for trastuzumab resistance in breast cancer, long-term outcomes of adjuvant therapies, and patient management in advanced prostate cancer. She also explores the implications of treatment decisions in metastatic cancer and the effects of therapies on patients' overall well-being.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (10)

Heikki Joensuu

University of Helsinki

FINLAND

View details

Julia Johansen

Professor

Copenhagen University Hospital

DENMARK

View details

Joe O'Sullivan

The Queen's University Belfast

UNITED KINGDOM

View details

Harri Kalevi Mustonen

University of Helsinki

FINLAND

View details

Mari Hämäläinen

University of Tampere

FINLAND

View details

Tiina Luukkaala

University of Tampere

FINLAND

View details

Claire Vale

University College London

UNITED KINGDOM

View details

Caroline Clarke

University College London

UNITED KINGDOM

View details

Pia Osterlund

Karolinska University Hospital

SWEDEN

View details

David Matheson

reader

University of Wolverhampton

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Pirkko-Liisa Kellokumpu-Lehtinen

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer

Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer

Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer

Long-term patient-reported outcomes from monarchE

Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

End-of-life Decision-making Differs Between a Cancer and a Dementia Patient

Radiotherapy-induced diffuse myocardial fibrosis in early-stage breast cancer patients – multimodality imaging study with six-year follow-up

Collaborators (10)

Heikki Joensuu

Julia Johansen

Joe O'Sullivan

Harri Kalevi Mustonen

Mari Hämäläinen

Tiina Luukkaala

Claire Vale

Caroline Clarke

Pia Osterlund

David Matheson

Make your next move.